Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | NCK1 | P16333 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30745612 | 1.00 | NQO2 (0.70) | NQO2KDM4EMAPTALDH1A1L3MBTL1 | |
| SCHEMBL9927345 | 0.89 | NQO2 (0.85) | NQO2KDM4EMAPTALDH1A1L3MBTL1 | |
| SCHEMBL2756741 | 0.89 | NQO2 (0.85) | NQO2KDM4EMAPTALDH1A1L3MBTL1 | |
| SCHEMBL21131352 | 0.86 | NQO2 (0.81) | NQO2KDM4EMAPTALDH1A1L3MBTL1 | |
| SCHEMBL18511341 | 0.86 | NQO2 (0.59) | NQO2KDM4EMAPTALDH1A1L3MBTL1 | |
| SCHEMBL15383508 | 0.84 | KDM4E (0.61) | NQO2KDM4EMAPTALDH1A1L3MBTL1 | |
| SCHEMBL14764615 | 0.84 | NQO2 (0.57) | NQO2KDM4EMAPTALDH1A1L3MBTL1 | |
| SCHEMBL18873137 | 0.84 | NQO2 (0.57) | NQO2KDM4EMAPTALDH1A1L3MBTL1 | |
| SCHEMBL14764426 | 0.84 | NQO2 (0.57) | NQO2KDM4EMAPTALDH1A1L3MBTL1 | |
| SCHEMBL28286262 | 0.84 | NQO2 (0.57) | NQO2KDM4EMAPTALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567372-A | Piperidine oxidation free radical derivative, preparation method and application thereof in flow battery | 合肥工业大学 | 2024-02-20 | — | — | CN | claimed |
| EP-2119717-B1 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as DPP IV inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2018-01-17 | — | — | EP | claimed |
| US-8697868-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-15 | — | — | US | claimed |
| US-7645763-B2 | dipeptidylpeptidase-IV inhibitors; antidiabetic agents, antiarthritic agents, obesity, allograft transplantation, and osteoporosis caused by calcitonin; 1,3-disubstituted-7-(2-butyn-1-yl)-8-(3-aminopiperidin-1-yl)-xanthine compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-01-12 | — | — | US | claimed |
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | claimed |
| EP-1758905-B1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DDP-IV INHIBITOR | BOEHRINGER INGELHEIM INT (DE) | 2009-04-29 | — | — | EP | claimed |
| EP-1720875-B1 | 8- [3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2008-12-10 | — | — | EP | claimed |
| US-20050234108-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | claimed |
| US-20050187227-A1 | 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-25 | — | — | US | claimed |
| EP-0517989-B1 | Bleach bath and its use in a silver dye bleaching process | JAHLEEL CORP (PA) | 1998-03-18 | — | — | EP | claimed |
| EP-0014688-B1 | PROCESS FOR THE TREATMENT OF SILVER DYE-BLEACHING MATERIALS, AQUEOUS PREPARATION THEREFOR, CONCENTRATE AND PROCESS FOR MAKING THE PREPARATION | CIBA-GEIGY AG (CH) | 1983-03-23 | — | — | EP | claimed |
| US-4304846-A | USING MIXTURES OF A 1,4- OR 1,2-DIAZINE AS BLEACHING CATALYSTS; PREFERENTIAL REDOX POTENTIALS | CIBA-GEIGY AG (CH) | 1981-12-08 | — | — | US | claimed |
| EP-0014688-A2 | Process for the treatment of silver dye-bleaching materials, aqueous preparation therefor, concentrate and process for making the preparation | CIBA-GEIGY AG (CH) | 1980-08-20 | — | — | EP | claimed |
| WO-2025215566-A1 | NON-AQUEOUS REDOX FLOW BATTERIES | ENI S.P.A. (IT) | 2025-10-16 | — | — | WO | disclosed |
| US-20240133963-A1 | FLOW BATTERY | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-04-25 | — | — | US | disclosed |
| CN-117567372-A | Piperidine oxidation free radical derivative, preparation method and application thereof in flow battery | 合肥工业大学 | 2024-02-20 | — | — | CN | disclosed |
| US-4197123-A | SUBTRACTIVE | CIBA-GEIGY AG (CH) | 1980-04-08 | — | — | US | disclosed |
| US-4186008-A | STRONG ACID, WATER-SOLUBLE IODIDE, NON-QUATERNIZED QUINOXALINE OR PYRAZINE, ANIT-OXIDANT, QUATERNARY AMMONIUM SALT OF AMINE SALT | CIBA-GEIGY AKTIENGESELLSCHAFT (CH) | 1980-01-29 | — | — | US | disclosed |
| US-4046566-A | PROCESS FOR THE PRODUCTION OF MASKED POSITIVE COLOR IMAGES BY THE SILVER DYE BLEACH PROCESS USING SILVER COMPLEX DIFFUSION | CIBA-GEIGY AG (CH) | 1977-09-06 | — | — | US | disclosed |
| US-4014698-A | ACIDS, IODIDE COMPOUNDS, OXIDIZERS, DIAZINE COMPOUND | CIBA-GEIGY AG (CH) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP7 | NQO2 956/4885KDM4E 1036/4885MAPT 295/4885 |
| US-20050234108-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | DPP8, DPP4, DPP7 | NQO2 947/4885KDM4E 1140/4885MAPT 330/4885 |
| US-20050187227-A1 | 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition | DPP8, DPP4, DPP7 | NQO2 821/4885KDM4E 1025/4885MAPT 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.